WINTON GROUP Ltd Sells 38,730 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

WINTON GROUP Ltd lowered its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 29.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 92,235 shares of the company's stock after selling 38,730 shares during the period. WINTON GROUP Ltd owned about 0.07% of Vir Biotechnology worth $677,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the business. SBI Securities Co. Ltd. bought a new position in Vir Biotechnology during the 4th quarter worth $60,000. PNC Financial Services Group Inc. raised its holdings in Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after purchasing an additional 1,999 shares during the last quarter. KBC Group NV lifted its position in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc bought a new stake in shares of Vir Biotechnology in the 4th quarter valued at $74,000. Finally, Virtu Financial LLC acquired a new stake in shares of Vir Biotechnology during the fourth quarter worth $94,000. Institutional investors and hedge funds own 65.32% of the company's stock.

Insider Buying and Selling

In other news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the sale, the director now directly owns 708,295 shares in the company, valued at $6,948,373.95. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at $726,264.40. This trade represents a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,859 shares of company stock worth $326,458. 15.60% of the stock is owned by insiders.

Vir Biotechnology Trading Down 9.0 %

Vir Biotechnology stock traded down $0.58 during trading on Thursday, hitting $5.90. 295,943 shares of the company were exchanged, compared to its average volume of 1,311,834. The company has a market capitalization of $809.14 million, a P/E ratio of -1.51 and a beta of 1.17. The business's 50 day moving average is $8.56 and its 200 day moving average is $8.32. Vir Biotechnology, Inc. has a 52 week low of $5.86 and a 52 week high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.09. The firm had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Equities analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Thursday, February 27th. Leerink Partners boosted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. JPMorgan Chase & Co. upped their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a report on Thursday, January 9th. Finally, Barclays lifted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.67.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).